Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 296.41M | 275.81M | 268.06M | 270.92M | 256.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 296.41M | 275.81M | 268.06M | 270.92M | 256.26M |
| Cost of Revenue | 170.37M | 157.28M | 147.34M | 143.57M | 132.59M |
| Gross Profit | 126.04M | 118.53M | 120.72M | 127.35M | 123.68M |
| SG&A Expenses | 81.58M | 77.74M | 73.52M | 72.50M | 68.33M |
| Depreciation & Amortization | 33.17M | 30.15M | 30.92M | 32.39M | 32.96M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 304.57M | 282.08M | 268.40M | 265.43M | 248.72M |
| Operating Income | -8.16M | -6.28M | -340.00K | 5.49M | 7.54M |
| Income Before Tax | -7.33M | -5.49M | 6.31M | 1.29M | -23.55M |
| Income Tax Expenses | -4.64M | -5.62M | -1.52M | -1.65M | -945.40K |
| Earnings from Continuing Operations | -2.68 | 0.13 | 7.83 | 2.94 | -22.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.68M | 130.90K | 7.83M | 2.94M | -22.61M |
| EBIT | -8.16M | -6.28M | -340.00K | 5.49M | 7.54M |
| EBITDA | 28.32M | 27.12M | 33.90M | 40.99M | 42.16M |
| EPS Basic | -0.03 | 0.00 | 0.08 | 0.03 | -0.22 |
| Normalized Basic EPS | -0.05 | -0.05 | 0.00 | 0.02 | 0.03 |
| EPS Diluted | -0.04 | -0.01 | 0.07 | 0.02 | -0.22 |
| Normalized Diluted EPS | -0.05 | -0.05 | 0.00 | 0.02 | 0.03 |
| Average Basic Shares Outstanding | 399.46M | 400.94M | 402.64M | 404.17M | 407.35M |
| Average Diluted Shares Outstanding | 400.31M | 401.78M | 403.48M | 404.58M | 407.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |